Wall Street Analysts Think Haemonetics (HAE) Could Surge 25.58%: Read This Before Placing a Bet
The mean of analysts' price targets for Haemonetics (HAE) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
Compared to Estimates, Haemonetics (HAE) Q2 Earnings: A Look at Key Metrics
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Tops Q2 Earnings and Revenue Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.99 per share a year ago.
Haemonetics (HAE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top -and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week primary observation period. Despite the stock price trading lower by 20%, the HAE treatment program continues on using NTLA-2002 in the phase 3 HAELO study. The global hereditary angioedema treatment market size is projected to reach $17.31 billion by the end of 2032.
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
Robust Plasma Sales, New Innovations Aid Haemonetics Stock
HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why You Should Add HAE Stock in Your Portfolio Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
